Latest Headlines
-
Oxford BioDynamics Receives Reimbursement Code For EpiSwitch Prostate Screening (PSE) Test
10/3/2023
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform, confirms the assignment and publication of a Proprietary Laboratory Analysis Code (PLA Code) by the American Medical Association’s CPT (Current Procedural Terminology) Editorial Board (https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes).
-
EntroGen Receives FDA Approval For CRCdx® RAS Mutation Detection Kit as Companion Diagnostic For Vectibix®
10/3/2023
The U.S. Food and Drug Administration (FDA) has granted approval for EntroGen's CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix® (panitumumab), a targeted therapy used in the treatment of colorectal cancer.
-
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization
10/3/2023
Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel.
-
CLEARSTEM Skincare Introduces Its First Ever Acne Lab Test
10/3/2023
CLEARSTEM Skincare (CLEARSTEM), the non-toxic, clean skincare brand, announced its telehealth debut with the launch of its CLEARSTEM Acne Lab Test. CLEARSTEM's revolutionary Acne Lab Test introduces a new era of skincare designed to identify consumer's unique root cause(s) of acne and provide a personalized treatment plan.
-
Fluxergy Launches New In-House Streptococcus equi ss equi Rapid PCR Assay
10/2/2023
Fluxergy, a company focused on multiplex, multimodal point-of-care (POC) laboratory testing, announced today that it has released their latest rapid PCR assay Streptococcus equi ss equi* to detect the SeM/eqbE gene from an equine nasal swab sample.
-
FDA Proposes Rule Aimed At Helping To Ensure Safety And Effectiveness Of Laboratory Developed Tests
9/29/2023
Today, the U.S. Food and Drug Administration announced a proposed rule regarding laboratory developed tests, or LDTs, which play an important role in healthcare. The rule is aimed at helping to ensure the safety and effectiveness of these tests, which are used in a growing number of health care decisions and for which concerns have been raised for many years.
-
Mars Completes Acquisition Of SYNLAB Vet, A European Provider Of Specialist Veterinary Laboratory Diagnostics
9/29/2023
Mars, Incorporated (“Mars”) today announced that it has completed its previously announced acquisition of the assets of SYNLAB Vet from SYNLAB Group.
-
Innovative Health Diagnostics Debuts New LabFlow Platform To Enhance At-Home Testing Capabilities For Digital Health Companies
9/29/2023
Innovative Health Diagnostics ("IHDLab" or the "Company"), a CLIA- and FDA-registered lab that provides access to accurate, clinical testing, today announced that the Company has launched LabFlow, a new API platform that is part of IHDLab's Diagnostics-as-a-Service ("DaaS") offering, to seamlessly connect with digital health companies' and enhance the efficiency and scalability of their at-home testing capabilities.
-
Point32Health And GRAIL Expand Pilot Access To Galleri Multi-Cancer Early Detection Blood Test
9/28/2023
Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the expansion of their pilot to offer GRAIL’s groundbreaking Galleri multi-cancer early detection screening test.
-
Anbio Biotechnology To Present At AACC Middle East 2023 On October 7th, 2023
9/28/2023
Anbio Biotechnology ("Anbio"), a leading global diagnostic device and assay company, has announced its participation in the AACC Middle East 2023 in Dubai on October 7-8, 2023. Middle East is a significant region for healthcare and medical laboratory and Anbio is looking forward to establishing more business cooperation with local partners and provide high quality IVD products in the Middle East through this event.